Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?

Inzucchi SE, Fitchett D, Jurišić-Eržen D, Woo V, Hantel S, Janista C, Kaspers S, George JT, Zinman B; EMPA-REG OUTCOME® Investigators.

Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13938. [Epub ahead of print]

PMID:
31789445
2.

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial.

Kosiborod MN, Jhund P, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køeber L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjöstrand M, Langkilde AM, McMurray JJV.

Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044138. [Epub ahead of print]

PMID:
31736335
3.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.

Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, Demets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjöstrand M, Langkilde AM, Jhund PS, McMurray JJV.

Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044133. [Epub ahead of print] No abstract available.

PMID:
31736328
4.

Reports of Lactic Acidosis Attributed to Metformin, 2015-2018.

Flory JH, Hennessy S, Bailey CJ, Inzucchi SE.

Diabetes Care. 2019 Oct 9. pii: dc190923. doi: 10.2337/dc19-0923. [Epub ahead of print]

PMID:
31597667
5.

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.

Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kiš SG, Kaspers S, George JT, Fitchett D.

Age Ageing. 2019 Nov 1;48(6):859-866. doi: 10.1093/ageing/afz096.

PMID:
31579904
6.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators.

N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.

PMID:
31535829
7.

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, Mc-Guire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M.

Circulation. 2019 Oct 29;140(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.042929. Epub 2019 Sep 16.

PMID:
31524498
8.

Diabetes prevention and cardiovascular complications.

Inzucchi SE, Viscoli CM, Young LH, Kernan WN.

Diabetologia. 2019 Nov;62(11):2161-2162. doi: 10.1007/s00125-019-04999-3. Epub 2019 Sep 14. No abstract available.

PMID:
31522231
9.

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.

Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE.

Eur Heart J. 2019 Aug 31. pii: ehz621. doi: 10.1093/eurheartj/ehz621. [Epub ahead of print]

PMID:
31504427
10.

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.

McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators.

Eur J Heart Fail. 2019 Nov;21(11):1402-1411. doi: 10.1002/ejhf.1548. Epub 2019 Jul 15.

PMID:
31309699
11.

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, Koitka-Weber A.

Am J Kidney Dis. 2019 Nov;74(5):713-715. doi: 10.1053/j.ajkd.2019.03.432. Epub 2019 Jun 27. No abstract available.

PMID:
31255334
12.

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21.

PMID:
31142441
13.

Understanding Contemporary Use of Thiazolidinediones.

Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS, Kosiborod M.

Circ Heart Fail. 2019 Jun;12(6):e005855. doi: 10.1161/CIRCHEARTFAILURE.118.005855.

PMID:
31129998
14.

Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?

Testani JM, Inzucchi SE, Voors AA.

Circulation. 2019 May 21;139(21):2383-2385. doi: 10.1161/CIRCULATIONAHA.119.038854. No abstract available.

PMID:
31107618
15.

Evidence supports prediabetes treatment.

Neumiller JJ, Kalyani RR, Herman WH, Grant RW, Wysham CH, Inzucchi SE, Hirsch IB, Fonseca VA, Buse JB, Barrett EJ.

Science. 2019 Apr 26;364(6438):341-342. doi: 10.1126/science.aax3548. No abstract available.

PMID:
31023917
16.

Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes.

Inzucchi SE, Fonseca V.

J Diabetes Complications. 2019 Jun;33(6):462-464. doi: 10.1016/j.jdiacomp.2019.03.003. Epub 2019 Mar 21. No abstract available.

PMID:
31003925
17.

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators.

Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21.

18.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
19.

Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.

Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN; IRIS Investigators.

JAMA Neurol. 2019 May 1;76(5):526-535. doi: 10.1001/jamaneurol.2019.0079. Erratum in: JAMA Neurol. 2019 Mar 18;:.

PMID:
30734043
20.

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D, George JT, Zinman B.

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31. No abstract available.

PMID:
30705060
21.

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.

McGuire DK, Marx N, Johansen OE, Inzucchi SE, Rosenstock J, George JT.

Diabetes Obes Metab. 2019 May;21(5):1073-1078. doi: 10.1111/dom.13645. Epub 2019 Mar 12.

PMID:
30690856
22.

Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry.

Fan W, Song Y, Inzucchi SE, Sperling L, Cannon CP, Arnold SV, Kosiborod M, Wong ND.

Diabetes Obes Metab. 2019 May;21(5):1121-1127. doi: 10.1111/dom.13625. Epub 2019 Feb 14.

PMID:
30609214
23.

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.

24.

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee and Investigators.

Circulation. 2019 Jan 15;139(3):366-375. doi: 10.1161/CIRCULATIONAHA.118.038341.

PMID:
30586726
25.

Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk.

Viscoli CM, Kent DM, Conwit R, Dearborn JL, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH, Kernan WN; IRIS Trial Investigators.

Stroke. 2018 Dec 10:STROKEAHA118022745. doi: 10.1161/STROKEAHA.118.022745. [Epub ahead of print]

PMID:
30580725
26.

Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease.

Dearborn JL, Viscoli CM, Inzucchi SE, Young LH, Kernan WN.

Int J Stroke. 2019 Aug;14(6):639-645. doi: 10.1177/1747493018816425. Epub 2018 Dec 3.

PMID:
30507360
27.

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P.

Diabetes Obes Metab. 2019 Mar;21(3):720-725. doi: 10.1111/dom.13579. Epub 2018 Dec 11.

28.

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B.

Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759. No abstract available.

PMID:
30354665
29.

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.

Claggett B, Lachin JM, Hantel S, Fitchett D, Inzucchi SE, Woerle HJ, George JT, Zinman B.

Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810. No abstract available.

PMID:
30354516
30.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

31.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators.

Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4.

32.

Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR).

Arnold SV, McGuire DK, Inzucchi SE, Tang F, Mehta SN, Lam CSP, Goyal A, Sperling LS, Wong ND, Hammar N, Fenici P, Kosiborod M.

J Diabetes Complications. 2018 Nov;32(11):1035-1039. doi: 10.1016/j.jdiacomp.2018.02.009. Epub 2018 Aug 9.

PMID:
30177468
33.

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators.

N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.

34.

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.

Lupsa BC, Inzucchi SE.

Diabetologia. 2018 Oct;61(10):2118-2125. doi: 10.1007/s00125-018-4663-6. Epub 2018 Aug 22. Review.

PMID:
30132031
35.

Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).

Arnold SV, Echouffo-Tcheugui JB, Lam CSP, Inzucchi SE, Tang F, McGuire DK, Goyal A, Maddox TM, Sperling LS, Fonarow GC, Masoudi FA, Kosiborod M.

Am Heart J. 2018 Sep;203:25-29. doi: 10.1016/j.ahj.2018.05.016. Epub 2018 Jun 18.

PMID:
30015065
36.

Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting.

Rdzak GM, Whitman LM, Inzucchi SE.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):217-222. doi: 10.1177/2042018818771433. Epub 2018 Apr 28.

37.

Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.

Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz ES, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN; IRIS Investigators.

Circulation. 2018 Sep 18;138(12):1210-1220. doi: 10.1161/CIRCULATIONAHA.118.034763.

38.

Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.

Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS.

Am Heart J. 2018 Aug;202:39-48. doi: 10.1016/j.ahj.2018.03.012. Epub 2018 Mar 29.

PMID:
29803985
39.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
40.

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B.

Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.

41.

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.

Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.

Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Review.

PMID:
29735306
42.

Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis.

Morgan CL, Inzucchi SE, Puelles J, Jenkins-Jones S, Currie CJ.

Diabetes Obes Metab. 2018 Sep;20(9):2140-2147. doi: 10.1111/dom.13344. Epub 2018 Jun 4.

PMID:
29732718
43.

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators.

Diabetologia. 2018 Jul;61(7):1522-1527. doi: 10.1007/s00125-018-4630-2. Epub 2018 Apr 30.

PMID:
29713728
44.

Hypoglycemia in type 2 diabetes: understanding patients' and physicians' knowledge and experience.

Fisher SJ, Huang X, Pawaskar M, Witt EA, Rajpathak S, Shankar RR, Inzucchi SE.

Endocrine. 2018 Jun;60(3):435-444. doi: 10.1007/s12020-018-1545-0. Epub 2018 Feb 19.

PMID:
29460218
45.

Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease.

Inzucchi SE.

Endocrinol Metab Clin North Am. 2018 Mar;47(1):137-152. doi: 10.1016/j.ecl.2017.10.011. Review.

PMID:
29407048
46.

Diabetes medications and cardiovascular disease: at long last progress.

Lupsa BC, Inzucchi SE.

Curr Opin Endocrinol Diabetes Obes. 2018 Apr;25(2):87-93. doi: 10.1097/MED.0000000000000400. Review.

PMID:
29369916
47.

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.

Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022. No abstract available.

48.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

49.

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM.

Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.

PMID:
29203583
50.

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.

Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, George JT, Zinman B.

Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13. No abstract available.

PMID:
29133602

Supplemental Content

Loading ...
Support Center